UF Health Cancer Center | Strategic Alliance Partners

The University of Florida Health Cancer Center stands alone in the state of Florida in its unique ability to blend comprehensive patient care and innovative research in a collaborative, multidisciplinary environment. It boasts a membership of more than 300 researchers and clinicians from across the University of Florida and UF Health, the Southeast’s most comprehensive academic health center on the main campus of one of the nation’s top five public research universities. The Cancer Center is dedicated to providing leading-edge cancer care and conducting original research to prevent, detect, treat and ultimately cure cancer while addressing the unique challenges of the cancer burden faced by the population we serve. UF Health includes more than 30,000 faculty and staff and manages more than 3 million inpatient and outpatient visits each year by leveraging three not-for-profit hospital systems — UF Health Shands, UF Health Jacksonville and UF Health Central Florida — that include 10 hospitals. In 2023, the center became the 72nd NCI-Designated Cancer Center and the only one based at a public university in the state of Florida.

Connect with us:

Latest from UF Health Cancer Center

Dr Sahin on the Design of the Northstar Response Assay in Advanced GI Cancer

April 10, 2024

Video

Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.

Dr Sahin on the Utility of the Northstar Response Assay in GI Cancer

March 28, 2024

Video

Ilyas Sahin, MD, discusses the potential utility of Northstar Response assay in patients with advanced gastrointestinal cancer.

Dr Sahin on the Potential Use of Northstar Response in GI Cancer

January 29, 2024

Video

Ilyas Sahin, MD, discusses an assessment of the Northstar Response in patients with advanced gastrointestinal cancer undergoing active treatment.

Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRC

July 31, 2023

Video

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer

Dr Rogers on the NEO-Nal-IRI Trial in Pancreatic Adenocarcinoma

July 21, 2023

Video

Sherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.

Dr Hitchcock on the Rationale for the ERAsur Trial in Limited mCRC

June 15, 2023

Video

Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.

Dr Doonan on the Evaluation of IRAK-4 Inhibition With Emavusertib in Metastatic Brain Melanoma

May 03, 2023

Video

Bently P. Doonan, MD, discusses the evaluation of targeted inhibition of IRAK-4 with emavusertib in the treatment of metastatic brain melanoma.

Dr Sahin on the Investigation of Milademetan and ONC201 in Solid Tumors

May 03, 2023

Video

Ilyas Sahin, MD, discusses the investigation of milademetan in combination with imipridone ONC201 as a synergistic combination in solid tumors.

Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR Mutations

April 10, 2023

Video

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer

April 05, 2023

Video

Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.

Traveling Through the Lung Cancer Treatment Paradigm: Taking TKI-Related AEs Into Consideration for NSCLC

March 15, 2023

Video

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Traveling Through the Lung Cancer Treatment Paradigm: Oral Etoposide

March 08, 2023

Video

In this fifth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses instances where oral etoposide could be utilized for patients with small cell lung cancer.

Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold Tumors

March 01, 2023

Video

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Traveling Through the Lung Cancer Treatment Paradigm: Managing irAEs With Corticosteroids

March 01, 2023

Video

In this fourth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the management of immune-related adverse effects and the goal of mitigating steroid use for patients with lung cancer.

Traveling Through the Lung Cancer Treatment Paradigm: Taking Advantage of Neoadjuvant Therapy

February 22, 2023

Video

In this third episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the expanding role of neoadjuvant therapy in non–small cell lung cancer and efforts to better identify patients who can benefit from curative-intent treatment.

Dr. Ramnaraign on the Investigation of Atezolizumab Plus Tivozanib in CRPC

February 20, 2023

Video

Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.

Traveling Through the Lung Cancer Treatment Paradigm: Biomarker Guidance in NSCLC

February 15, 2023

Video

In this second episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the need for additional circulating biomarkers beyond PD-L1 in non–small cell lung cancer.

Pembrolizumab Plus Total Neoadjuvant Therapy Improves Long-Term OS in Locally Advanced Rectal Cancer

February 13, 2023

Article

Thomas J. George, MD, FACP, highlights the long-term data from the NRG-GI002 trial, the next steps for exploring subsets of patients who may benefit from the addition of pembrolizumab or veliparib to total neoadjuvant therapy, and what the use of total neoadjuvant therapy has meant for patients with stage II/III locally advanced rectal cancer.

Dr. Sahin on the Background of the IMbrave 151 Trial in Biliary Tract Cancer

February 11, 2023

Video

Ilyas Sahin, MD, discusses the background and findings of the phase 2 IMbrave 151 trial in advanced biliary tract cancer.

Dr. Rogers on the Potential for ctDNA to Aid Second-line Treatment Decisions in mCRC

February 10, 2023

Video

Sherise Rogers, MD, MPH, discusses the potential of utilizing circulating tumor DNA to help guide second-line treatment decisions in patients with metastatic colorectal cancer.